Diabetes & obesity cure: BF Biosciences launches ‘Zeptide®’

KARACHI: BF Biosciences Limited has launched Zeptide® (Tirzepatide), an advanced treatment for Type 2 diabetes and obesity, marking a major milestone in Pakistan’s biopharmaceutical sector.

In a notice to the Pakistan Stock Exchange, the company said Tirzepatide, approved by the US FDA, is a dual agonist for GLP-1 and GIP receptors, helping regulate blood glucose levels and promote weight reduction.

Produced at BF Biosciences’ European technology-based facility, Zeptide® is available in a pre-filled syringe format to enhance safety, precision, and patient compliance.

A company spokesperson said the launch reflects the firm’s commitment to offering world-class, locally manufactured biologics that meet international standards. The drug underwent rigorous testing in both the United States and Pakistan for quality and potency.

The company noted that the development was part of its IPO proceeds utilization plan, underscoring its focus on reinvesting in Pakistan’s healthcare ecosystem.

BF Biosciences, which already leads the GLP-1 segment with its Sematide® (semaglutide) brand, said the introduction of Zeptide® would strengthen its portfolio amid rising diabetes and obesity rates in the country.

With Pakistan ranking among the countries with the highest diabetes prevalence globally, the need for effective and accessible treatments remains critical. According to the company, more than nine million Pakistanis remain undiagnosed, while 57 percent of women and 41 percent of men are overweight or obese — conditions that increase the risk of Type 2 diabetes by up to seven times.

Copyright Business Recorder, 2025